CADTH Canadian Drug Expert Committee recommendation. Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis.

CADTH Canadian Drug Expert Committee recommendation. indication: ankylosing spondylitis. Ixekizumab (Taltz -- Eli Lilly Canada Inc.) :

Show other versions (5)

The CADTH Canadian Drug Expert Committee (CDEC) recommends that ixekizumab be reimbursed for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy only if the following conditions are met.

Saved in:
Bibliographic Details
Online Access: Full text
Corporate Author: CADTH Canadian Drug Expert Committee (Author)
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : CADTH, 2020
Edition:Version 1.0.
Series:Common drug review clinical review report.
Subjects:
Spondylitis, Ankylosing > drug therapy.
Antibodies, Monoclonal, Humanized > therapeutic use.
Antibodies, Monoclonal, Humanized > economics.
Cost-Benefit Analysis.
Insurance, Health, Reimbursement.
Canada.

Internet

Full text

Similar Items